![]() ![]() The coprimary outcomes were the percent change in anti–factor Xa activity after andexanet treatment and the percentage of patients with excellent or good hemostatic efficacy at 12 hours after the end of the infusion, with hemostatic efficacy adjudicated on the basis of prespecified criteria. The patients received a bolus of andexanet, followed by a 2-hour infusion. We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. ![]() The most trusted, influential source of new medical knowledge and clinical best practices in the world.Īndexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. Information and tools for librarians about site license offerings. ![]() Valuable tools for building a rewarding career in health care. The authorized source of trusted medical research and education for the Chinese-language medical community. The most advanced way to teach, practice, and assess clinical reasoning skills. Information, resources, and support needed to approach rotations - and life as a resident. The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams. NEW! Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care delivery.Ĭoncise summaries and expert physician commentary that busy clinicians need to enhance patient care. NEW! A digital journal for innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. ![]()
0 Comments
Leave a Reply. |